In a recent review of prostate cancer screening guidelines, researchers found that data supporting the efficacy of prostate-specific antigen (PSA) testing are not entirely compelling and that screening should not include men at average risk for prostate cancer if they are younger than 50 years of age or older than 75 years of age (2). Here, KLK3 is linked to prostate carcinoma.